A Glance on Nanovaccine : A Potential Approach for Disease Prevention
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
There are several vaccines available for preventing various bacterial and viral infections, but still, there are many challenges that require the development of noninvasive, more efficient, and active vaccines. The advancement in biotechnological tools has provided safer antigens, such as nucleic acids, proteins etc., but due to their lower immunogenic property, adjuvants of stronger immune response are required. Nanovaccines are effective vaccines when compared with conventional vaccines as they can induce both Humoral and cell-mediated immune responses and also provide longer immunogenic memory. The nanocarriers used in vaccines act as adjuvant. They provide site-specific delivery of antigens and can be used in conjugation with immunostimulatory molecules for enhancing adjuvant therapy. The nanovaccines avoid degrading cell pathways and provide effective absorption into blood vessels. The higher potential of nanovaccines to treat various diseases, such as Acquired Immuno Deficiency Syndrome, Cancer, Tuberculosis, Malaria and many others, along with their immunological mechanisms and different types, have been discussed in the review.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Current pharmaceutical biotechnology - (2023) vom: 11. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garg, Akash [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cell-mediated. |
|---|
| Anmerkungen: |
Date Revised 20.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0113892010254221231006100659 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363534067 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363534067 | ||
| 003 | DE-627 | ||
| 005 | 20231226093542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0113892010254221231006100659 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363534067 | ||
| 035 | |a (NLM)37861010 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garg, Akash |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Glance on Nanovaccine |b A Potential Approach for Disease Prevention |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a There are several vaccines available for preventing various bacterial and viral infections, but still, there are many challenges that require the development of noninvasive, more efficient, and active vaccines. The advancement in biotechnological tools has provided safer antigens, such as nucleic acids, proteins etc., but due to their lower immunogenic property, adjuvants of stronger immune response are required. Nanovaccines are effective vaccines when compared with conventional vaccines as they can induce both Humoral and cell-mediated immune responses and also provide longer immunogenic memory. The nanocarriers used in vaccines act as adjuvant. They provide site-specific delivery of antigens and can be used in conjugation with immunostimulatory molecules for enhancing adjuvant therapy. The nanovaccines avoid degrading cell pathways and provide effective absorption into blood vessels. The higher potential of nanovaccines to treat various diseases, such as Acquired Immuno Deficiency Syndrome, Cancer, Tuberculosis, Malaria and many others, along with their immunological mechanisms and different types, have been discussed in the review | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell-mediated. | |
| 650 | 4 | |a Humoral | |
| 650 | 4 | |a Immune response | |
| 650 | 4 | |a Infectious Diseases | |
| 650 | 4 | |a Nanovaccine | |
| 650 | 4 | |a Vaccine | |
| 700 | 1 | |a Chopra, Himansu |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Talever |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhary, Ramkumar |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Rutvi |e verfasserin |4 aut | |
| 700 | 1 | |a Tankara, Abhishek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d 2000 |g (2023) vom: 11. Okt. |w (DE-627)NLM11369072X |x 1873-4316 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:11 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0113892010254221231006100659 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 11 |c 10 | ||